Cellular and humoral response after mRNA-1273 SARS-CoV-2 vac
According to preliminary data, seroconversion after mRNA SARS-CoV-2 vaccination might be unsatisfactory in Kidney Transplant Recipients (KTRs). However, a recent study shows that the mRNA-1273 SARS-CoV-2 vaccine elicits either cellular or humoral response in many of KTRs.

Researchers prospectively studied 148 recipients of either kidney (133) or kidney-pancreas (15) grafts with the assessment of IgM/IgG spike (S) antibodies and ELISpot against the nucleocapsid (N) and the S protein at baseline and two weeks after receiving the second dose of the mRNA-1273 (Moderna) vaccine.

At baseline, 31 patients had either IgM/IgG or ELISpot positivity and were considered to be SARS-CoV-2-pre-immunized, while 117 patients had no signs of either cellular or humoral response and were considered SARS-CoV-2-naïve.

--After vaccination, naïve patients who developed either humoral or cellular response were finally 65.0%, of which 29.9% developed either IgG or IgM and 35.0% S-ELISpot positivity.

--Factors associated with vaccine unresponsiveness were diabetes and treatment with anti-thymocytes globulins during the last year.

--Side effects were consistent with that of the pivotal trial and no DSAs developed after vaccination.

In conclusion, the mRNA-1273 SARS-CoV-2 vaccine elicits either cellular or humoral response in almost two-thirds of KTRs.

American Journal of Transplantation
Source: https://doi.org/10.1111/ajt.16701
Like
Comment
Share